Skip to main content

Excessive vigorous exercise impairs cognitive function through a muscle-derived mitochondrial pretender.

Cell metabolism2025-12-05PubMed
Total: 84.5Innovation: 9Impact: 8Rigor: 8Citation: 9

Summary

Excessive vigorous exercise elevates lactate, triggering muscle secretion of mitochondria-derived vesicles (otMDVs) that enter hippocampal neurons, displace endogenous mitochondria, and impair synaptic energetics via cGAS–STING–KIF5 inhibition and PAF–syntaphilin–mediated anchoring disruption. A PAF-neutralizing antibody mitigated synapse loss and cognitive deficits; human data linked higher circulating otMDVs with cognitive impairment.

Key Findings

  • Lactate from excessive vigorous exercise induces muscle secretion of mitochondria-derived vesicles (otMDVs) with high mtDNA and PAF marker.
  • otMDVs traffic to hippocampal neurons, replace endogenous mitochondria, and cause synaptic energy crisis.
  • Released mtDNA activates cGAS–STING, inhibiting KIF5-dependent mitochondrial transport; PAF cooperates with syntaphilin to block mitochondrial anchoring.
  • PAF-neutralizing antibody prevents otMDV hippocampal entry and ameliorates synapse loss and cognitive impairment; human association corroborated.

Clinical Implications

Supports avoiding overtraining in at-risk individuals and motivates development of biomarkers (circulating otMDVs/PAF) and targeted interventions (e.g., PAF blockade) to protect cognition.

Why It Matters

Reveals a previously unrecognized muscle-to-brain organelle transfer mechanism for exercise-induced cognitive decline, identifying actionable targets (PAF, cGAS–STING–KIF5) for prevention.

Limitations

  • Rodent exercise paradigms may not fully reflect human training patterns and thresholds.
  • Translatability of PAF as a therapeutic target and safety of long-term blockade remain to be established.

Future Directions

Define dose–response thresholds for otMDV induction in humans, develop clinical assays for circulating otMDVs/PAF, and test targeted interventions (PAF or cGAS–STING modulation) in controlled trials.

Study Information

Study Type
Basic/Mechanistic research
Research Domain
Pathophysiology
Evidence Level
III - Mechanistic preclinical evidence with human associative data
Study Design
OTHER